News

The FDA approval of setmelanotide for patients 4 years and older offers a targeted therapy to address the underlying biology of acquired hypothalamic obesity.

A study found that the UTICalc tool effectively and accurately detects urinary tract infections in febrile children.

Clinical and family goals should guide the selection between high-dose CIMT and bimanual therapy.

A poll found that while many parents worry about youth driving accidents, most fail to recognize unsafe habits in their own children behind the wheel.

Shara Bialo, MD, explains why immunologic screening for islet autoantibodies is essential to identifying type 1 diabetes in its presymptomatic stages.

Palynziq provides a significant new genotype-independent therapy for patients 12 years and older to help manage and reduce blood phenylalanine levels.

Chad Wells, PhD, shares evidence-based strategies to improve MenACWY 2-dose series completion and address racial and socioeconomic disparities in vaccination.

Kathleen Adelgais, MD, MPH, highlights the critical role of family-centered protocols in overcoming readiness barriers and improving emergency outcomes for children.

A first-of-its-kind approval for hypothalamic obesity offers earlier, targeted treatment in children.

Researchers found that the Pediatric Psychiatry Colocalized Consult Clinic significantly reduces wait times and improves resident confidence.

FDA green-lights Imcivree for acquired hypothalamic obesity in patients 4 years and older, delivering major reductions in BMI and hunger in phase 3.

Aristides Maniatis, MD, FAAP explains how Sogroya reduces treatment burden and improves adherence for pediatric patients with growth disorders.

A recent study has reported increasing rates of self-injury up to 4.3% among youths, with girls showing higher rates than boys.

Integrating an automated tobacco treatment system into routine pediatric visits significantly increased smoking cessation rates among mothers.

A study found that cognitive and developmental advantages for firstborns appear within the first year of life.

The FDA sanctioned Johnson & Johnson’s once-daily oral pill for adults and adolescents with moderate to severe plaque psoriasis.

Pediatricians can use brief dietary screenings and policy advocacy to help families transition from ultra-processed foods toward minimally processed alternatives.

A study found that high consumption of ultra-processed foods in early childhood is associated with increased risks of anxiety, hyperactivity, and aggression.

A trial found that high-frequency oscillatory ventilation is a promising first-line therapy that significantly lowers the risk of bronchopulmonary dysplasia.

After a decade of clinical assessments failed to meet DSM-5 criteria, a chromosomal microarray revealed the genetic truth behind a complex neurodevelopmental presentation.

Kara Margolis, MD, highlights how early life stress influences gastrointestinal health through the gut-brain axis.

The INTEGUMENT-OLE study results highlight the long-term efficacy and safety of roflumilast cream for pediatric patients with atopic dermatitis.

A phase 3 trial shows that lebrikizumab improves skin clearance and itch in infants and children with moderate to severe atopic dermatitis.

Get caught up with Contemporary Pediatrics. This list helps you navigate our top stories from the week, all in one place.

A study found children who experience a mild traumatic brain injury are more likely to develop new or chronic sleep problems vs typically developing children.

Secukinumab now treats moderate to severe hidradenitis suppurativa in patients 12 years and older, making it the first IL‑17A biologic option for teens.

A study found that prompt blood sugar control following a gestational diabetes diagnosis can reduce a child's risk of obesity.

A study found that day-to-day fluctuations in screen use have a minimal impact on subsequent sleep outcomes among children and adolescents.